NCT03433196View on ClinicalTrials.gov

Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases

PHASE3CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

June 7, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

October 10, 2018

Conditions
Hypercholesterolemia in Coronaory Heart Disease
Interventions
DRUG

HS-25 and Atorvastatin

HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily

DRUG

Atorvastatin

Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily

All Listed Sponsors
lead

Zhejiang Hisun Pharmaceutical Co. Ltd.

INDUSTRY

NCT03433196 - Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases | Biotech Hunter | Biotech Hunter